Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

All SEC Filings

Date Form Description PDF XBRL Pages
02/16/18 424B5 Prospectus filed pursuant to Rule 424(b)(5) 39
02/16/18 8-K Current report filing 95
02/15/18 8-K Current report filing
Documents
6
02/13/18 8-K Current report filing
Documents
5
02/07/18 8-K Current report filing
Documents
5
01/08/18 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions 18
12/05/17 8-K Current report filing
Documents
27
12/04/17 8-K Current report filing 2
11/14/17 8-K Current report filing
Documents
11
11/13/17 10-Q Quarterly report pursuant to Section 13 or 15(d) 38
RSS